Reckitt Benckiser notified the FDA that the company is voluntarily discontinuing the supply of Suboxone (buprenorphine and naloxone sublingual tablets).  Suboxone sublingual tablets and films are indicated for maintenance treatment of opioid dependence as part of a complete treatment plan to include counseling and psychosocial support.

The company received analysis of data from U.S. Poison Control Centers on September 15, 2012 that found significantly higher rates of accidental pediatric exposure with Suboxone tablets than with Suboxone film (buprenorphine and naloxone sublingual film). The rates for Suboxone tablets were 7.8–8.5 times greater depending on the study period.

The company has stated that Suboxone tablets can still be dispensed and ordered until the customer is switched to another alternative or there is no longer a supply of medication available in the marketplace.

Suboxone tablets will remain available in 8mg/2mg and 2mg/0.5mg dosage strengths until supply runs out.

For more information call (877) 782-6966 or visit